RenDx Fungiplex Assay
RenDx Fungiplex Assay gains CE mark
Invasive fungal diseases (IFDs) are emerging as an increasingly important cause of life-threatening infections and represent a significant cause of morbidity and mortality in patients who receive immunosuppressive therapies, such as those prescribed for solid organ transplants (SOT) and hematopoietic stem cell transplants (HCT), and in patients suffering immune compromising conditions such as AIDS.
The Renishaw Diagnostics RenDx Fungiplex Assay is a multiplex PCR in vitro test for the qualitative detection of Candida and Aspergillus DNA extracted from EDTA whole blood, EDTA plasma or serum. The assay is designed for use with the RenDx Multiplex Assay System, an automation and detection platform that allows processing of up to 45 samples from post extraction to result in around 7 hours. The assay identifies 12 Candida and Aspergillus species using a unique detection technology known as surface enhanced resonance Raman scattering (SERRS). The high sensitivity provided by this method offers the potential for early diagnosis while quality controlled manufacture ensures that the user can have full confidence in assay quality and reproducibility.
Analytical sensitivity and specificity
Based on testing of 2415 plasmid and simulated samples at relevant clinical concentrations.